Comparing the effects of Conbercept and Ranibizumab on proliferation and migration in RF/6A cells
Related Articles |
To conduct a comparative research on the differences and mechanisms of the effects of Conbercept and Ranibizumab on Rhesus choroidoretinal endothelial cells (RF/6A cells) proliferation, migration effects induced by VEGF. Methods RF/6A cells were divided into six groups, namely control group, VEGF group, Conbercept group, Ranibizumab group, Conbercept+VEGF group and Ranibizumab+VEGF group. CCK-8 assay, Transwell chambers, AnnexinV-FITC/PI double staining flow cytometry, Western blot and real-time PCR were separately adopted to detect cell proliferation, cell migration, cell apoptosis, the levels of AKT, p-AKT, P38MAPK and p-P38MAPK protein expression and the relative expression of AKT mRNA and P38MAPK mRNA. Results ① Compared with control group, the cell poliferation decreased in a concentration-dependent manner by Conbercept and Ranibizumab treatment. The optimal concentration and effect time of Conbercept and Ranibizumab were determined as 225 μg/mL and 24 h. ② Cell proliferation and cell migration were significantly decreased in Conbercept group and Ranibizumab group, but meaningfully increased in VEGF group. Compared with VEGF group, Conbercept+VEGF group and Ranibizumab+VEGF group decreased. ③ Cell apoptosis decreased in VEGF group, but increased in Conbercept and Ranibizumab group. Compared with VEGF group, Cell apoptosis increased in Conbercept and Ranibizumab+VEGF group. ④ There were no differences about the expression of AKT and P38MAPK among groups. Compared with control group, the expression of p-AKT, p-P38MAPK, AKT mRNA and P38MAPK mRNA were down-regulated in Conbercept and Ranibizumab group, while up-regulated in VEGF group. Compared with VEGF group, the expression of p-AKT, p-P38MAPK, AKT mRNA and P38MAPK mRNA were down-regulated in Conbercept and Ranibizumab+VEGF group. Conclusions The research results show that Conbercept and Ranibizumab have obvious inhibiting effects on cell proliferation, migration and related protein expression, while they accelerate cell apoptotis. Nevertheless, there are no statistical significance between the impacts of Conbercept and Ranibizumab on the cells.